Advertisement
Screener

Vaxart, Inc. (VXRT) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period

2.0 / 5 stars · 35/87 Roast Me

Vaxart, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period

Vaxart, Inc. (VXRT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 254.52 thousand shares for the 3-month period ending 2016-09-30, per its 10-Q filed 2016-11-08.

Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2017-09-01

  • Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2016-09-30 was 254.52K shares, a 30454.98% increase year-over-year.
  • Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2015-09-30 was 833.00 shares, a 99.80% decline year-over-year.
  • Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2015-06-30 was 83.47K shares, a 3.90% decline year-over-year.
  • Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2015-03-31 was 2.83K shares.
  • Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2016 was 249.36K shares, a 53.06% decline from fiscal 2015.
  • Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2015 was 531.25K shares, a 391.29% increase from fiscal 2014.
  • Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2014 was 108.14K shares.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month
2016-09-30254.52K shares
10-Q · filed 2016-11-08
2016-06-30249.36K shares
10-K · filed 2017-09-01
2015-09-30833.00 shares
10-Q · filed 2015-11-06
84.31K shares
derived: sum of 2 quarters · filed 2016-09-13
87.14K shares
derived: sum of 3 quarters · filed 2016-09-13
114.18K shares
derived: sum of 4 quarters · filed 2016-09-13
2015-06-3083.47K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-13
86.31K shares
derived: sum of 2 quarters · filed 2016-09-13
113.35K shares
derived: sum of 3 quarters · filed 2016-09-13
531.25K shares
10-K · filed 2016-09-13
2015-03-312.83K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-05-08
29.87K shares
derived: sum of 2 quarters · filed 2015-05-08
447.78K shares
10-Q · filed 2015-05-08
534.64K shares
derived: sum of 4 quarters · filed 2015-05-08
2014-12-3127.04K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-02-06
444.94K shares
10-Q · filed 2015-02-06
531.81K shares
derived: sum of 3 quarters · filed 2015-02-06
2014-09-30417.90K shares
10-Q · filed 2014-11-07
504.77K shares
derived: sum of 2 quarters · filed 2014-11-07
2014-06-3086.87K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2014-09-30
108.14K shares
10-K · filed 2014-09-30
2014-03-3121.27K shares
10-Q · filed 2014-05-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
Kalaris Therapeutics, Inc. (KLRS)United States$0.073B-2.19
Atara Biotherapeutics, Inc. (ATRA)United States$0.086B-6.48
Pelthos Therapeutics Inc. (PTHS)United States$0.086B-1.20
CHAMPIONS ONCOLOGY, INC. (CSBR)United States$0.070B-68.02
COGNITION THERAPEUTICS INC (CGTX)United States$0.090B-6.52
BioStem Technologies, Inc. (BSEM)United States$0.069B
Eloxx Pharmaceuticals, Inc. (ELOX)United States$0.065B
MiNK Therapeutics, Inc. (INKT)United States$0.063B-5.37
Cardiff Oncology, Inc. (CRDF)United States$0.101B-2.22
EXOZYMES INC. (EXOZ)United States$0.058B